Cox regression analysis of the validation cohort
| Univariable Cox . | OS . | NRM . | TTR . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| EASIX-1y (twofold increase) | 1.61 | 1.42-1.82 | < .001 | 1.76 | 1.52-2.03 | < .001 | 1.22 | 1.03-1.46 | .023 |
| Multivariable Cox | n = 851 events = 162 | n = 851, events = 101 | n = 851, events = 110 | ||||||
| EASIX-1y (twofold increase) | 1.60 | 1.41-1.83 | <.001 | 1.77 | 1.50-2.05 | <.001 | 1.22 | 1.02-1.46 | .031 |
| Age above 50 y (yes vs no) | 1.26 | 0.91-1.76 | .168 | 1.56 | 1.02-2.40 | .041 | 1.20 | 0.80-1.82 | .378 |
| Recipient sex (male vs female) | 1.15 | 0.83-1.61 | .403 | 1.17 | 0.76-1.78 | .475 | 1.09 | 0.73-1.62 | .670 |
| HLA-mismatch (yes vs no) | 0.94 | 0.63-1.39 | .756 | 0.91 | 0.55-1.49 | .702 | 0.95 | 0.58-1.58 | .858 |
| RIC (yes vs no) | 0.98 | 0.66-1.47 | .934 | 1.23 | 0.75-2.03 | .416 | 1.02 | 0.62-1.68 | .943 |
| ATG (yes vs no) | 1.26 | 0.91-1.77 | .169 | 1.15 | 0.74-1.78 | .530 | 1.64 | 1.11-2.44 | .014 |
| MTX (yes vs no) | 1.24 | 0.83-1.86 | .290 | 1.13 | 0.68-1.88 | .664 | 0.86 | 0.52-1.41 | .542 |
| Diagnosis (myeloid vs lymphoid) | 1.14 | 0.80-1.65 | .464 | 1.10 | 0.69-1.76 | .675 | 0.80 | 0.53-1.22 | .304 |
| History of acute GVHD | 0.88 | 0.61-1.28 | .507 | 1.75 | 1.00-3.04 | .049 | 0.42 | 0.28-0.63 | < .001 |
| Univariable Cox . | OS . | NRM . | TTR . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| EASIX-1y (twofold increase) | 1.61 | 1.42-1.82 | < .001 | 1.76 | 1.52-2.03 | < .001 | 1.22 | 1.03-1.46 | .023 |
| Multivariable Cox | n = 851 events = 162 | n = 851, events = 101 | n = 851, events = 110 | ||||||
| EASIX-1y (twofold increase) | 1.60 | 1.41-1.83 | <.001 | 1.77 | 1.50-2.05 | <.001 | 1.22 | 1.02-1.46 | .031 |
| Age above 50 y (yes vs no) | 1.26 | 0.91-1.76 | .168 | 1.56 | 1.02-2.40 | .041 | 1.20 | 0.80-1.82 | .378 |
| Recipient sex (male vs female) | 1.15 | 0.83-1.61 | .403 | 1.17 | 0.76-1.78 | .475 | 1.09 | 0.73-1.62 | .670 |
| HLA-mismatch (yes vs no) | 0.94 | 0.63-1.39 | .756 | 0.91 | 0.55-1.49 | .702 | 0.95 | 0.58-1.58 | .858 |
| RIC (yes vs no) | 0.98 | 0.66-1.47 | .934 | 1.23 | 0.75-2.03 | .416 | 1.02 | 0.62-1.68 | .943 |
| ATG (yes vs no) | 1.26 | 0.91-1.77 | .169 | 1.15 | 0.74-1.78 | .530 | 1.64 | 1.11-2.44 | .014 |
| MTX (yes vs no) | 1.24 | 0.83-1.86 | .290 | 1.13 | 0.68-1.88 | .664 | 0.86 | 0.52-1.41 | .542 |
| Diagnosis (myeloid vs lymphoid) | 1.14 | 0.80-1.65 | .464 | 1.10 | 0.69-1.76 | .675 | 0.80 | 0.53-1.22 | .304 |
| History of acute GVHD | 0.88 | 0.61-1.28 | .507 | 1.75 | 1.00-3.04 | .049 | 0.42 | 0.28-0.63 | < .001 |